Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research. In Vitro Cirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, which is associated with inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibition of gene expression includes effects on alternative splicing. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Orally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Cirtuvivint
CAS number：2143917-62-6 molecular formula：C24H25N7O
overview
compound introduction
Specs
| Chinese alias | 西尔图维文特 | ||
| English alias | - | ||
| CAS number | 2143917-62-6 | molecular formula | C24H25N7O |
| molecular weight | 427.50 g/mol | Exact mass | ≥98% |
| PSA | 79.200 Ų | logp | 2.400 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
